MARCO and neoplasm: The TME was altered, featuring more pro-inflammatory macrophages, and treatment with anti-MARCO not only led to tumor shrinkage but also augmented the effects of anti-CTLA-4 immunotherapy through an NK cell-dependent mechanism.